Eli Lilly Technical Analysis | Eli Lilly Trading: 2022-02-03 | IFCM UAE
IFC Markets Online CFD Broker

Eli Lilly Technical Analysis - Eli Lilly Trading: 2022-02-03

Eli Lilly Technical Analysis Summary

Accelerometer arrow
Strong SellSellNeutralBuyStrong Buy

Above 251.77

Buy Stop

Below 232.67

Stop Loss

Ara Zohrabian
Ara Zohrabian
Senior Analytical Expert
Articles2681
IndicatorSignal
RSI Neutral
MACD Buy
Donchian Channel Buy
MA(200) Buy
Fractals Buy
Parabolic SAR Buy

Eli Lilly Chart Analysis

Eli Lilly Chart Analysis

Eli Lilly Technical Analysis

The technical analysis of the Eli Lilly stock price chart on daily timeframe shows #S-LLY, Daily is rebounding above the 200-day moving average MA(200) which is rising itself. We believe the bullish momentum will continue after the price breaches above the upper boundary of Donchian channel at 251.77. This level can be used as an entry point for placing a pending order to buy. The stop loss can be placed below the lower boundary of Donchian channel at 232.67. After placing the order, the stop loss is to be moved every day to the next fractal low, following Parabolic indicator signals. Thus, we are changing the expected profit/loss ratio to the breakeven point. If the price meets the stop loss level (232.67) without reaching the order (251.77), we recommend cancelling the order: the market has undergone internal changes which were not taken into account.

Fundamental Analysis of Stocks - Eli Lilly

Eli Lilly stock gained 1% ahead of fourth-quarter and full-year 2021 results today, before market open. Will the Eli Lilly stock price continue rebounding?

Eli Lilly is an American pharmaceutical company which develops and sells human pharmaceuticals worldwide. Its global competitors include companies like GlasxoSmithKline, Bristol-Myers Squibb, Merck, Pfizer and others. Eli Lilly capitalization is about $227.5 billion and the stock is trading at P/E ratio (Trailing Twelve Months) of 63.3 currently and Forward P/E of around 27.6 compared with the 24.3 Forward P/E of the pharmaceutical industry as a whole. The company earned $27.76B revenue (ttm) and Return on Equity (ttm) of 92.24%. Since the beginning of 2017, Eli Lilly has outperformed all other big pharmaceutical companies: from January 1, 2017 through December 10, 2021 Eli Lilly stock generated a 270% total return, more than any of its competitors during the same time frame. Last Friday Eli Lilly announced plans to invest over $1 billion to create a new manufacturing site in Concord, North Carolina. Over the last five years, the company has invested over $4 billion in global manufacturing, including more than $2 billion in the US. The company also announced plans to invest $500 million in a new biopharmaceutical manufacturing facility in Limerick, Ireland. Drugs that analysts expect will account for majority of company’s revenue increase in 2022 include Jardiance, a type 2 diabetes treatment it markets in partnership with Boehringer Ingelheim, and Tyvyt, a PD-1 inhibitor Lilly jointly developed in China with collaboration partner Innovent Biologics. Eli Lilly's stock price is retracing up to its all-time high after falling over 10% since the start of 2022. While the company has missed earnings expectations in three of the trailing four quarters and beat in one, the consensus forecast is Lilly should beat expectations when it reports fourth-quarter and full-year results today.

IFCM Trading Academy - New era in Forex education
Pass Your Course:
  • Get Certificate
trading academy

The best trading conditions and high-level services for our clients

We are ready to assist you on any issue 24 hours a day.

Note:
This overview has an informative and tutorial character and is published for free. All the data, included in the overview, are received from public sources, recognized as more or less reliable. Moreover, there is no guarantee that the indicated information is full and precise. Overviews are not updated. The whole information in each overview, including opinion, indicators, charts and anything else, is provided only for familiarization purposes and is not financial advice or а recommendation. The whole text and its any part, as well as the charts cannot be considered as an offer to make a deal with any asset. IFC Markets and its employees under any circumstances are not liable for any action taken by someone else during or after reading the overview.

Close support
Call to WhatsApp Call to telegram Call Back